GlobeNewswire: Pandion Therapeutics, Inc. Contains the last 10 of 11 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:05:17ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/02/22/2179580/0/en/Pandion-Therapeutics-Presents-Preclinical-Data-Highlighting-Potential-of-Tissue-Tethered-PD-1-Agonist-to-Locally-Target-Autoimmune-Disease-at-the-nPOD-13th-Annual-Scientific-Meetin.html?f=22&fvtc=4&fvtv=60555Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting2021-02-22T13:30:00Z<![CDATA[WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today presented preclinical data on PT001, the Company’s tissue-tethered PD-1 agonist, at the Network for Pancreatic Organ Donors with Diabetes (nPOD) 13th Annual Scientific Meeting. The research, done in collaboration with St Vincent’s Institute of Medical Research in Australia and funded by JDRF and the JDRF T1D Fund, showed that PT001 treatment delayed the onset of hyperglycemia in a mouse model of Type 1 diabetes.]]>https://www.globenewswire.com/news-release/2021/02/18/2178051/0/en/Pandion-Therapeutics-to-Present-at-the-10th-Annual-SVB-Leerink-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=60555Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference2021-02-18T13:30:00Z<![CDATA[WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will present at the upcoming 10th Annual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 9:20 a.m. ET.]]>https://www.globenewswire.com/news-release/2021/01/04/2152594/0/en/Pandion-Therapeutics-Announces-Positive-Top-Line-Phase-1a-Clinical-Data-Showing-PT101-was-Well-Tolerated-and-Selectively-Expanded-Regulatory-T-cells.html?f=22&fvtc=4&fvtv=60555Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells2021-01-04T13:00:00Z<![CDATA[-Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in third-party clinical trials across multiple autoimmune diseases-PT101 maintained selectivity for regulatory T cells at all doses tested-Phase 1a/2b clinical trial in ulcerative colitis expected to start mid-2021 and Phase 2 clinical trial in systemic lupus erythematosus expected to start second half 2021-Phase 1a results to be presented in a conference call scheduled today at 8:30 a.m. ET]]>https://www.globenewswire.com/news-release/2020/12/03/2139078/0/en/Pandion-Therapeutics-Appoints-Katina-Dorton-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=60555Pandion Therapeutics Appoints Katina Dorton to its Board of Directors2020-12-03T13:00:00Z<![CDATA[WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion’s board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company’s board on December 2, 2020.]]>https://www.globenewswire.com/news-release/2020/11/16/2127734/0/en/Pandion-Therapeutics-Reports-Third-Quarter-2020-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=60555Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update2020-11-16T21:01:00Z<![CDATA[- Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; IND-enabling studies expected to initiate 4Q 2020- Presented preclinical data at FOCIS 2020 highlighting potential of TALON platform in autoimmune disease]]>https://www.globenewswire.com/news-release/2020/11/10/2123707/0/en/Pandion-Therapeutics-to-Present-at-the-Stifel-2020-Virtual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=60555Pandion Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference2020-11-10T13:00:00Z<![CDATA[WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will present at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 4:00 p.m. ET.]]>https://www.globenewswire.com/news-release/2020/10/28/2115865/0/en/Pandion-Therapeutics-Highlights-Potential-of-Modular-Biologics-Pipeline-for-the-Treatment-of-Autoimmune-Diseases-at-FOCIS-2020.html?f=22&fvtc=4&fvtv=60555Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 20202020-10-28T12:00:00Z<![CDATA[WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the presentation of preclinical data highlighting the potential of its modular biologics pipeline for the treatment of autoimmune diseases at the Federation of Clinical Immunology Societies (FOCIS) 2020 virtual annual meeting.]]>https://www.globenewswire.com/news-release/2020/09/24/2098611/0/en/Pandion-Therapeutics-to-Participate-in-Panel-Discussion-at-Stifel-2020-Immunology-Inflammation-Virtual-Summit.html?f=22&fvtc=4&fvtv=60555Pandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit2020-09-24T12:00:00Z<![CDATA[WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will participate in a panel discussion at the upcoming Stifel Immunology & Inflammation Summit on Thursday, October 1, 2020 at 3:00 p.m. ET.]]>https://www.globenewswire.com/news-release/2020/09/10/2091643/0/en/Pandion-Therapeutics-to-Present-at-Morgan-Stanley-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=60555Pandion Therapeutics to Present at Morgan Stanley Global Healthcare Conference2020-09-10T12:00:00Z<![CDATA[WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will participate in a fireside chat at the upcoming Morgan Stanley 18th Annual Global Healthcare Conference on Thursday, September 17th, 2020 at 2:00 p.m. ET.]]>https://www.globenewswire.com/news-release/2020/08/31/2086434/0/en/Pandion-Reports-Second-Quarter-2020-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=60555Pandion Reports Second Quarter 2020 Financial Results and Provides Business Update2020-08-31T20:05:00Z<![CDATA[- Completed successful IPO providing approximately $153 million in gross proceeds; cash runway extended through first half of 2024]]>